Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility
The observations do not pose any risk to site's compliance standards or its business continuity
The observations do not pose any risk to site's compliance standards or its business continuity
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023
Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
Subscribe To Our Newsletter & Stay Updated